Challenges in the Use of Targeted Therapies in Non-Small Cell Lung Cancer.
Cancer Res Treat
; 54(2): 315-329, 2022 Apr.
Article
em En
| MEDLINE
| ID: mdl-35209703
ABSTRACT
Precision oncology has fundamentally changed how we diagnose and treat cancer. In recent years, there has been a significant change in the management of patients with oncogene-addicted advanced-stage NSCLC. Increasing amounts of identifiable oncogene drivers have led to the development of molecularly targeted drugs. Undoubtedly, the future of thoracic oncology is shifting toward increased molecular testing and the use of targeted therapies. For the most part, these novel drugs have proven to be safe and effective. As with all great innovations, targeted therapies pose unique challenges. Drug toxicities, resistance, access, and costs are some of the expected obstacles that will need to be addressed. This review highlights some of the major challenges in the use of targeted therapies in NSCLC and provides guidance for the future strategies.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Carcinoma Pulmonar de Células não Pequenas
/
Neoplasias Pulmonares
Tipo de estudo:
Guideline
Limite:
Humans
Idioma:
En
Revista:
Cancer Res Treat
Ano de publicação:
2022
Tipo de documento:
Article
País de afiliação:
Estados Unidos